London: A new study published in the The Lancet Neurology journal has revealed that the drug, Galantamine, improves the quality of life for sufferers of Alzheimer’s Disease.

The research showed that it improves the condition of patients and extends their life expectancy.

But in the UK, the £2.50 a day treatment, is not available to patients when symptoms become too severe.

Professor Alistair Burns of the University of Manchester, who led the study said: “The results from a very conservative viewpoint do not support withdrawal of such treatment.”